Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic
By A Mystery Man Writer
Description
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://europepmc.org/articles/PMC7891472/bin/41408_2021_432_Fig2_HTML.jpg)
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. - Abstract - Europe PMC
Health-related quality of life change over time. Estimated change in
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://www.researchgate.net/publication/326677471/figure/fig4/AS:960059005730825@1605907312921/FACT-MM-TOI-change-from-pre-ASCT-baseline-values-adjusted-FACT-MM-TOI-scale-is-0-to_Q320.jpg)
PDF) Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41409-023-02160-8/MediaObjects/41409_2023_2160_Fig1_HTML.png)
Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://i1.rgstatic.net/publication/307890281_Health-Related_Quality_of_Life_Results_From_the_Open-Label_Randomized_Phase_III_ASPIRE_Trial_Evaluating_Carfilzomib_Lenalidomide_and_Dexamethasone_Versus_Lenalidomide_and_Dexamethasone_in_Patients_Wit/links/57d3333708ae5f03b48cda24/largepreview.png)
PDF) Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41409-021-01521-5/MediaObjects/41409_2021_1521_Fig2_HTML.png)
Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
How I treat elderly patients with plasma cell dyscrasias
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://i1.rgstatic.net/publication/318710321_Lenalidomide_Maintenance_After_Autologous_Stem-Cell_Transplantation_in_Newly_Diagnosed_Multiple_Myeloma_A_Meta-Analysis/links/5ea16aa9299bf14389406c0d/largepreview.png)
PDF) Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://ous-research.no/stavik/images/Group%20members/PM-Sandset_web.jpg)
OUH - Scientific personell
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs41687-024-00691-2/MediaObjects/41687_2024_691_Figc_HTML.png)
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00277-018-3446-y/MediaObjects/277_2018_3446_Fig6_HTML.png)
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://www.tandfonline.com/cms/asset/f7fe4146-61c1-4ebd-a1dd-b52a31bbb410/ifon_a_12332187_f0001.jpg)
Full article: INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://www.researchgate.net/publication/343113435/figure/fig2/AS:958462418751509@1605526656942/Progression-free-survival-PFS-and-overall-survival-OS-in-the-intention-to-treat_Q320.jpg)
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
![Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-019-0181-0/MediaObjects/41408_2019_181_Fig3_HTML.png)
Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
from
per adult (price varies by group size)